School of Medicine,
Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, Enayetallah A, Beasley KN, Rampal N, Howard JF, CHAMPION MG Study Group. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid. 2022; 1 (5)
Lafreniere M, Dixon SE, “Thoughts and Perceptions of Risdiplam from Adults with SMA.” CureSMA Researcher and Clinical Care Meeting, Anaheim, CA (June 2022, Poster presentation).
Petluru M, Dixon SE, “Worsening Upper Extremity Weakness Seen as a Side Effect of Risdiplam in Adults with Spinal Muscular Atrophy.” CureSMA Researcher and Clinical Care Meeting, Anaheim, CA (June 2022, Poster presentation).
Chen E, Dixon S, Naik R, Noone JM, Buchenberger JD, Whitmire SM, Mills R, Arnold W. Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers. Muscle Nerve. 2021 Mar;63(3):311-319. PubMed PMID: 33184859
Monnette A, Chen E, Hong D, Bazzano A, Dixon S, Arnold WD, Shi L. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021 Jan 20;16(1):36. PubMed PMID: 33472673
Chen E., Dixon, S.E., Naik, R., Noone, J., Buchenberger, D., Whitmire, S., Mills, R., Arnold, W. (2021). Early experiences in the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers. Muscle & Nerve, 63(13), 311-319.
Monnette, A., Chen, E., Hong, D., Bazzano, A., Dixon, S.E., Arnold, WD., Shi, L. (2021). Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet Journal of Rare Diseases, 20;16(1):36
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021 Jan;20(1):49-59.
Arnold, WD., Chen, E., Naik, R., Noone, J., Whitmire, S., Buchenberger, D., Dixon, S.E. Clinical Experience of Spinal Muscular Atrophy (SMA) Treatment: Physician’s Perspective.
Chen E., Naik, R., Noone, J., Buchenberger, D., Whitmire, Dixon, S.E, S., Arnold, WD. Early experiences in the Treatment of Spinal Muscular Atrophy: Results from a large survey of patients and caregivers.
Chen, E., Bawa, K., Noone, J., Whitmire, S., Buchenberger, D., Arnold, WD., Dixon, S.E. Impact of Spinal Muscular Atrophy on Caregivers’ Daily Activities and Health-related Quality of Life.
Monnette, A., Chen, E., Hong, D., Bazzano, A., Dixon, S., Arnold, WD., Shi, L., Treatment Preference among Patients with Spinal Muscular Atrophy (SMA): A Discrete Choice Experiment.
Rocky Mountain Regional Veterans Administration Medical Center
1700 Wheeling St
Aurora, CO 80045
University of Colorado Hospital
Veterans Affairs Medical Center
Neurology, Board Certification
Conditions & Treatments
Brain and Nervous System - Neuromuscular Diseases
Brain and Nervous System
Neuromuscular disorders including: muscular dystrophies, acquired muscle diseases such as dermatomyositis and polymyositis, acquired peripheral nervous system disorders such as Guillain-Barre syndrome and CIDP.
MD, Indiana University School of Medicine
PhD, Indiana University - Indianapolis
BS, Indiana University System (IN)
East Tennessee State University Program
University of Colorado (University Hospital) Program, Chief Resident, Neurology (2016)
University of Colorado (University Hospital) Program, Neuromuscular Medicine